Markets:

Overview

News

Currencies

International

Treasuries

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

42.33 -1.17 (-2.69%)

Streaming Delayed Price Updated: 10:38 AM EST, Feb 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook ↗

April 28, 2025

Via Benzinga

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗

March 14, 2025

Via The Motley Fool

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗

March 06, 2025

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 30, 2025

Via Benzinga

Exploring Kiniksa Pharmaceuticals's Earnings Expectations ↗

October 28, 2024

Via Benzinga

Earnings Outlook For Kiniksa Pharmaceuticals ↗

February 27, 2024

Via Benzinga

Earnings Outlook For Kiniksa Pharmaceuticals ↗

October 30, 2023

Via Benzinga

NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

October 01, 2024

– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease –

From Kiniksa Pharmaceuticals, Ltd.

Via GlobeNewswire

KNSA Stock Earnings: Kiniksa Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

July 23, 2024

KNSA stock results show that Kiniksa Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday ↗

July 23, 2024

Via Benzinga

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 23, 2024

Via Benzinga

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

Via AB Newswire

Topics ETFs

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record...

Via TheNewswire.com

Topics ETFs

KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗

April 23, 2024

KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 02, 2024

Shares of Longboard Pharmaceuticals, Inc.

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

Earnings Scheduled For April 23, 2024 ↗

April 23, 2024

Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion.

Via Benzinga

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗

September 28, 2023

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Via Investor's Business Daily

5 Value Stocks In The Healthcare Sector ↗

September 11, 2023

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

August 21, 2023

Via Benzinga

Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+ ↗

August 16, 2023

Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Via Investor's Business Daily

ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 15, 2023

One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81.

Via Investor's Business Daily

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

August 15, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

Exelixis Stock Sees Rising Relative Strength Rating ↗

August 14, 2023

On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.

Via Investor's Business Daily

Dynavax Technologies Stock Sees Renewed Technical Strength ↗

August 07, 2023

Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.

Via Investor's Business Daily

Crude Oil Up 1%; Verizon Earnings Beat Views ↗

July 25, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 25, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.